Your browser doesn't support javascript.
loading
In vitro antifungal activity of fluconazole and voriconazole against non-Candida yeasts and yeast-like fungi clinical isolates.
Mandras, Narcisa; Roana, Janira; Scalas, Daniela; Fucale, Giacomo; Allizond, Valeria; Banche, Giuliana; Barbui, Anna; Li Vigni, Nicolò; Newell, Vance A; Cuffini, Anna Maria; Tullio, Vivian.
Affiliation
  • Mandras N; Department of Public Health and Paediatrics, Microbiology Division, University of Turin, Turin, Italy.
  • Roana J; Department of Public Health and Paediatrics, Microbiology Division, University of Turin, Turin, Italy.
  • Scalas D; Department of Public Health and Paediatrics, Microbiology Division, University of Turin, Turin, Italy.
  • Fucale G; Analysis Laboratory and Microbiology, C.T.O./C.R.F. Hospital, Turin, Italy.
  • Allizond V; Department of Public Health and Paediatrics, Microbiology Division, University of Turin, Turin, Italy.
  • Banche G; Department of Public Health and Paediatrics, Microbiology Division, University of Turin, Turin, Italy.
  • Barbui A; Microbiology Laboratory, S. Giovanni Battista Hospital, Turin, Italy.
  • Li Vigni N; Analysis Laboratory and Microbiology, Infermi Hospital, Biella, Italy.
  • Newell VA; Giles Scientific, Inc., Santa Barbara, California.
  • Cuffini AM; Department of Public Health and Paediatrics, Microbiology Division, University of Turin, Turin, Italy.
  • Tullio V; Department of Public Health and Paediatrics, Microbiology Division, University of Turin, Turin, Italy.
New Microbiol ; 38(4): 583-7, 2015 Oct.
Article in En | MEDLINE | ID: mdl-26485018
ABSTRACT
The risk of opportunistic infections caused by non-Candida yeasts and yeast-like fungi is increasingly common, mainly in immunocompromised patients. Appropriate first-line therapy has not been defined and standardized, mainly due to the low number of cases reported. To improve empirical treatment guidelines, we describe the susceptibility profile to fluconazole and voriconazole of 176 non-Candida yeasts and yeast-like fungi collected from hospitals in Piedmont, North West Italy from January 2009 to December 2013. The results showed that most isolates are susceptible to voriconazole (94%), but less susceptible to fluconazole (78%), suggesting that voriconazole could be used as first-line therapy in infections caused by these fungi.
Subject(s)
Key words
Search on Google
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Fluconazole / Voriconazole / Fungi / Mycoses / Antifungal Agents Type of study: Guideline Limits: Humans Country/Region as subject: Europa Language: En Journal: New Microbiol Journal subject: MICROBIOLOGIA Year: 2015 Type: Article Affiliation country: Italy
Search on Google
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Fluconazole / Voriconazole / Fungi / Mycoses / Antifungal Agents Type of study: Guideline Limits: Humans Country/Region as subject: Europa Language: En Journal: New Microbiol Journal subject: MICROBIOLOGIA Year: 2015 Type: Article Affiliation country: Italy